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Background:  Pharmacogenomics (PGx) in cardiovascular medicine is evolving rapidly, however little is known about how US cardiologists perceive 
and use PGx testing.
Methods:  We conducted an anonymous, cross-sectional, fax-based survey of US physicians in late 2008. The survey solicited demographic and 
professional profile characteristics, as well as PGx educational background, beliefs, practices, and preferred information sources. Surveys from 
respondents who self-identified as cardiologists were included in this analysis. Factors associated with cardiologists’ adoption of PGx testing were 
tested for statistical significance with chi-square and multivariate logistic regression analyses.
Results:  We surveyed 397,832 physicians and 10,303 (3%) completed surveys were returned. Respondent characteristics were similar to the 
overall US physician population by comparison with the American Medical Association MasterFile data. A total of 201 respondents self-identified as 
cardiologists, and nearly all (n=195, 99%) believed that a patient’s genetic profile influences response to drug therapy. A PGx test had been ordered 
or recommended by 16% (n=31) in the past 6 months, while 35% (n=68) anticipated doing so in the next six months. Among these PGx testing 
adopters, 55% reported postgraduate PGx education versus 29% with none. Univariate factors associated with ordering a PGx test in the previous 
6 months included feeling adequately informed about PGx testing (OR 4.42, CI 1.88-10.40, p<0.001), being more likely to report using genetic 
testing labs (OR 12.19, CI 4.87-30.49, p<0.001) and colleagues/other physicians (OR 2.37, CI 1.07-5.25, p=0.03) as sources of information on 
PGx testing. In multivariate analysis, cardiologists who ordered a PGx test in the previous 6 months were more likely to have had postgraduate PGx 
instruction (OR 8.60, 95%CI 2.80-26.40, p< 0.001).
Conclusion: Almost all sampled US cardiologists believe that a patient’s genetic makeup influences drug therapy response, however just 16% of 
cardiologists report having already adopted PGx testing into practice and 35% anticipate future adoption. Prior education exerted a strong influence 
on the adoption of PGx testing.
